A Study of Apalutamide in Chinese Participants With Non Metastatic Castration Resistant Prostate Cancer (NM-CRPC)

第4相完了 NCT04108208

対象疾患	Prostatic Neoplasms
相	第4相
スポンサー	Janssen Research & Development, LLC
ステータス	完了
参加者数	75 名
介入（薬剤）	Apalutamide, Androgen-deprivation Therapy (ADT)
開始日	2019年12月17日
完了日	2023年6月1日
結果公開日	2025年3月28日

概要

The purpose of this study is to compare the improvement in time to prostate specific antigen (PSA) progression (TTPP, as defined by Prostate Cancer Working Group 2 \[PCWG2\]) of apalutamide versus placebo in Chinese participants with high-risk non-metastatic castration resistant prostate cancer (NM-CRPC).

Time to Prostate Specific Antigen (PSA) Progression (TTPP) Based on Prostate Cancer Working Group 2 (PCWG2) Criteria

From randomization until first documented PSA progression (up to 3 years 3 months) · Months

Placebo Plus Androgen-deprivation Therapy (ADT)	NA Months
Apalutamide 240 mg Plus ADT	NA Months

p-value	=0.0052
Hazard Ratio (HR)	0.233 (95% CI 0.077–0.705)

BENITIONS で見る ClinicalTrials.gov の原文を見る

同じ疾患の他の治験

A Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate — Aragon Pharmaceuticals, Inc.
Propranolol Hydrochloride in Treating Patients With Prostate Cancer Undergoing Surgery — Wake Forest University Health Sciences
Testing the Safety of Different Doses of Olaparib Given Radium-223 for Men With Advanced P — National Cancer Institute (NCI)
M6620 and Carboplatin With or Without Docetaxel in Treating Patients With Metastatic Castr — National Cancer Institute (NCI)
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abirate — Janssen Research & Development, LLC
Testing Two Oral Drugs Combination (Cediranib and Olaparib) Compared to a Single Drug (Ola — National Cancer Institute (NCI)

すべての治験

このページは ClinicalTrials.gov の公開データをまとめたものです。医学的助言ではなく、投資助言でもありません。必ず専門医にご相談ください。

English 한국어 日本語中文 Русский